Advancing Novel Therapies
in Neuropsychiatry
for patients who have not found effective solutions for their disease

Clexio is a clinical-stage company designing novel drugs based on validated Mechanisms
of Action in NeuroPsychiatry

We are developing innovative therapies to address patients’ unmet needs in Major Depressive Disorder (MDD) and Epilepsy.

Our lead drug candidate (CLE-100) is currently being tested in Phase 2 multicenter studies in the United States.

Our second candidate (CLE-043) is currently in preclinical stage, with lead compound identified.

 

Learn More

A multi-asset pipeline

We are a multi-asset company with a rich and growing pipeline, from preclinical to Phase 2 development stages.

Program
Pre clinical
Phase 1
Phase 2
Phase 3

CLE-100
NMDA antagonist

CLE-043
KV7.2/3
channel opener

background-image

CLE-100

NMDA antagonist

Developing a new treatment paradigm for patients suffering from Major Depressive Disorder

LEARN MORE
background-image

CLE-043

KV7.2/3 channel opener
Skip to content